Rakuten Medical
在场
Rakuten Medical 的所有者是 Rakuten.
是其中之一......
Rakuten 是一家在股票代码 4755 (JP) 下上市的公司。
Rakuten 在 9 个国家有直接业务。Rakuten 拥有 22家子公司，其中包括 Cartera Commerce、Kobo 和 OverDrive。
他们在：
涉及Rakuten的并购和融资。
- Rakuten Medical 刚刚宣布为 119 筹款数百万美元。 (公布2024三月12号).
高管
查看带有其 22 名主要高管的组织结构图
Rakuten Medical 搜索最多的简介
- Hiroshi Mikitani, Chief Executive Officer and Chairman of the Board
- Kentaro Hyakuno, Director
- Hiroshi Mori, Director
创建提醒
跟踪 Rakuten Medical 的高管变动
生物技术
Rakuten 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Rakuten Medical 的最新新闻稿
- Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024 - Rakuten Medical - To conquer cancer.
- Rakuten Medical Announces New Management Team to Drive the Next Phase of Growth and Innovation - Rakuten Medical - To conquer cancer.
- Rakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting - Rakuten Medical - To conquer cancer.
- Rakuten Medical Announces Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to be Presented at ASCO 2024 - Rakuten Medical - To c
- Rakuten Medical’s Poster Presentation at AACR 2024 Demonstrates Reduction in Photoimmunotherapy-induced Edema in Mice with COX-2 Inhibition - Rakuten Medical - To conquer cancer.
- Rakuten Medical’s Upcoming Poster Presentation at AACR 2024: New Findings in Mouse Study to Manage Edema Associated with Photoimmunotherapy based on the Alluminox™ Platform - Rakuten Medical - To conquer cancer.
- Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform - Rakuten Medical - To conquer cancer.
- Over 20 Presentations on Alluminox Treatment (Photoimmunotherapy) at International Conferences in 2023 - Rakuten Medical - To conquer cancer.
- Three Invited Presentations on Alluminox Treatment (Photoimmunotherapy) at FHNO 2023 - Rakuten Medical - To conquer cancer.
- Rakuten Medical Announces First Patient Treatment in India in Global Phase 3 Trial of Alluminox Treatment (Photoimmunotherapy) using ASP-1929 for Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.
- View more press releases Close
通过电子邮件
